全球同类首创、一年给药两次的HIV预防药物落地海南博鳌乐城使用

Core Viewpoint - Gilead China has officially launched Lenacapavir, a groundbreaking HIV pre-exposure prophylaxis (PrEP) drug that requires administration only twice a year, in the Boao Lecheng International Medical Tourism Pilot Zone in Hainan [1] Group 1 - Lenacapavir has been approved for use in the United States since June, aimed at reducing the risk of HIV transmission through sexual contact for adults and adolescents weighing at least 35 kilograms [1]